Clinical Trials Search
Clinical Trial 18342
Interventions:G-CSF; MESNA; NY-ESO-1c259T; cyclophosphamide; cytoxan (cyclophosphamide)
Study Type: Treatment
Phase of Study: Phase I/II
- Benjamin Creelan
A Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to test the safety of genetically changed T cells and find out what effects, if any, they have in participants with lung cancer.
Primary: To evaluate the safety and tolerability of autologous genetically modified T cells (NY-ESO-1c259T) in HLA-A*0201, HLA-A*0205 and/or HLA-A*0206 positive subjects with NY-ESO-1 positive advanced NSCLC. Secondary: To evaluate the efficacy of NY-ESO-1c259T. To measure persistence of genetically modified cells in the body. To evaluate the phenotype and functionality of genetically modified cells isolated from peripheral blood or tumor post infusion. To evaluate NY-ESO-1 expression in tumor tissue, before and after treatment, and correlate with clinical response to treatment.